| Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised … B Burtness, KJ Harrington, R Greil, D Soulières, M Tahara, G de Castro, ... The Lancet 394 (10212), 1915-1928, 2019 | 2310 | 2019 |
| Azacitidine and venetoclax in previously untreated acute myeloid leukemia CD DiNardo, BA Jonas, V Pullarkat, MJ Thirman, JS Garcia, AH Wei, ... New England Journal of Medicine 383 (7), 617-629, 2020 | 1836 | 2020 |
| Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial S Horwitz, OA O'Connor, B Pro, T Illidge, M Fanale, R Advani, NL Bartlett, ... The Lancet 393 (10168), 229-240, 2019 | 689 | 2019 |
| Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a … M Attal, PG Richardson, SV Rajkumar, J San-Miguel, M Beksac, I Spicka, ... The Lancet 394 (10214), 2096-2107, 2019 | 633* | 2019 |
| Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non–germinal center B-cell diffuse large B-cell lymphoma A Younes, LH Sehn, P Johnson, PL Zinzani, X Hong, J Zhu, C Patti, ... Journal of Clinical Oncology 37 (15), 1285-1295, 2019 | 507 | 2019 |
| CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells Y Wei, YH Chen, LY Li, J Lang, SP Yeh, B Shi, CC Yang, JY Yang, CY Lin, ... Nature cell biology 13 (1), 87-94, 2011 | 430 | 2011 |
| Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia P Montesinos, C Recher, S Vives, E Zarzycka, J Wang, G Bertani, ... New England Journal of Medicine 386 (16), 1519-1531, 2022 | 254 | 2022 |
| The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma S Horwitz, OA O'connor, B Pro, L Trümper, S Iyer, R Advani, NL Bartlett, ... Annals of Oncology 33 (3), 288-298, 2022 | 132 | 2022 |
| Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma M Crump, S Leppä, L Fayad, JJ Lee, A Di Rocco, M Ogura, H Hagberg, ... J Clin Oncol 34 (21), 2484-2492, 2016 | 126 | 2016 |
| Smurf2‐mediated degradation of EZH2 enhances neuron differentiation and improves functional recovery after ischaemic stroke YL Yu, RH Chou, WC Shyu, SC Hsieh, CS Wu, SY Chiang, WJ Chang, ... EMBO molecular medicine 5 (4), 531-547, 2013 | 112 | 2013 |
| Measurable residual disease response and prognosis in treatment-naïve acute myeloid leukemia with venetoclax and azacitidine KW Pratz, BA Jonas, V Pullarkat, C Recher, AC Schuh, MJ Thirman, ... Journal of Clinical Oncology 40 (8), 855, 2022 | 107 | 2022 |
| Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a … U Platzbecker, RSM Wong, A Verma, C Abboud, S Araujo, TJ Chiou, ... The Lancet Haematology 2 (10), e417-e426, 2015 | 80 | 2015 |
| Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ... The Lancet 401 (10373), 269-280, 2023 | 79 | 2023 |
| Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter … P Montesinos, GJ Roboz, CE Bulabois, M Subklewe, U Platzbecker, ... Leukemia 35 (1), 62-74, 2021 | 77 | 2021 |
| Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall … DP Petrylak, R de Wit, KN Chi, A Drakaki, CN Sternberg, H Nishiyama, ... The Lancet Oncology 21 (1), 105-120, 2020 | 76 | 2020 |
| EZH2 regulates neuronal differentiation of mesenchymal stem cells through PIP5K1C-dependent calcium signaling YL Yu, RH Chou, LT Chen, WC Shyu, SC Hsieh, CS Wu, HJ Zeng, ... Journal of Biological Chemistry 286 (11), 9657-9667, 2011 | 72 | 2011 |
| A phase II study of arginine deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients HJ Tsai, SS Jiang, WC Hung, G Borthakur, SF Lin, N Pemmaraju, ... Scientific reports 7 (1), 11253, 2017 | 71 | 2017 |
| The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells JY Chen, YS Lai, HJ Tsai, CC Kuo, BL Yen, SP Yeh, HS Sun, WC Hung Scientific reports 6 (1), 32428, 2016 | 70 | 2016 |
| Myocyte enhancer factor-2 interacting transcriptional repressor (MITR) is a switch that promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by … YH Chen, FL Yeh, SP Yeh, HT Ma, SC Hung, MC Hung, LY Li Journal of Biological Chemistry 286 (12), 10671-10680, 2011 | 70 | 2011 |
| Epidemiology and risk factors for invasive fungal infections during induction chemotherapy for newly diagnosed acute myeloid leukemia: a retrospective cohort study MY Lien, CH Chou, CC Lin, LY Bai, CF Chiu, SP Yeh, MW Ho PloS one 13 (6), e0197851, 2018 | 63 | 2018 |
